SPOTLIGHT -
How to bill for bladder stone removal performed during cystoscopy
Correct code selection depends on whether procedure is simple or complex.
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Pembrolizumab/axitinib efficacy in ccRCC sustained at 5-year follow-up
At a median follow-up of 67.2 months, the combination of pembrolizumab and axitinib continued to show an overall survival and progression-free survival benefit over sunitinib monotherapy in the first-line setting.
2023 AUA highlights in benign urology
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Cabozantinib/atezolizumab does not improve PFS or OS in advanced RCC
“The addition of atezolizumab to cabozantinib did not result in improved clinical outcomes in patients with mRCC who progressed on or after prior ICI treatment,” said Toni K. Choueiri, MD.
Erdafitinib extends survival in post-immunotherapy, FGFR-altered urothelial cancer
In this patient population, erdafitinib reduced the risk of death by 36% versus physician's choice of chemotherapy.
